Desmopressin prescription safety in adult inpatients: a real-world tertiary centre experience
- PMID: 39854712
- PMCID: PMC11834999
- DOI: 10.1530/EC-24-0441
Desmopressin prescription safety in adult inpatients: a real-world tertiary centre experience
Abstract
Abstract: Omissions or delays in desmopressin can result in serious patient harm in patients with arginine vasopressin deficiency (AVP-D), formally known as cranial diabetes insipidus. Desmopressin administration practice in hospitals has not been thoroughly investigated previously. This study evaluated desmopressin prescription and administration practice at a large tertiary centre. A retrospective electronic case notes review of all admissions (≥24 h) with AVP-D between 2018 and 2021 at Sheffield Teaching Hospitals was undertaken. The outcomes were defined as the total number of missed and delayed doses, time to prescription and administration from admission and incidence of dysnatraemias. A qualitative survey to determine knowledge of AVP-D and desmopressin among staff members was also carried out. In total, 102 admissions were identified, of which 38% of admissions were via emergency department (ED). The total number of missed and delayed doses were 132/1315 (10.0%) and 139/1283 (10.9%), respectively. Of all admissions, 33% had ≥1 missed doses, while ≥1 doses were delayed in 54% admissions. ED rates of desmopressin prescription were low at 5%. The most common reasons documented for missed or delayed doses were unavailability of desmopressin followed by inability of the patient to take the medication. Median (interquartile range) prescription and administration times from admission were 5.6 (2.7-10.7) and 15.1 (8.7-27.0) h, respectively. The incidence of inpatient hypernatraemia and hyponatraemia was 7.6 and 30.4%, respectively. The staff survey showed below-average knowledge of the condition, advocating for an urgent need for education.
Plain language summary: AVP-D is a life-threatening condition requiring desmopressin to prevent severe dehydration and death. During hospitalisation, these patients are more vulnerable due to restricted desmopressin access and a lack of awareness among hospital staff. This study evaluates desmopressin prescription practice at a large European hospital and confirms that delays occur frequently in real world. We recommend that desmopressin should be listed as a critical drug and education packages should be introduced for hospital staff.
Keywords: arginine vasopressin deficiency; cranial diabetes insipidus; desmopressin; patient safety.
Conflict of interest statement
No relevant conflicts of interest from all co-authors.
Similar articles
-
Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study.Eur J Endocrinol. 2015 Mar;172(3):243-50. doi: 10.1530/EJE-14-0719. Epub 2014 Nov 27. Eur J Endocrinol. 2015. PMID: 25430399
-
Desmopressin as an adjuvant to opioids or NSAIDs in treatment of renal colic: a nationwide register-based study.Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1155-60. doi: 10.1002/pds.3875. Epub 2015 Sep 9. Pharmacoepidemiol Drug Saf. 2015. PMID: 26349846
-
SOCIETY FOR ENDOCRINOLOGY CLINICAL GUIDANCE: Inpatient management of cranial diabetes insipidus.Endocr Connect. 2018 Jul;7(7):G8-G11. doi: 10.1530/EC-18-0154. Endocr Connect. 2018. PMID: 29930026 Free PMC article.
-
Desmopressin administration in children with central diabetes insipidus: a retrospective review.J Pediatr Endocrinol Metab. 2013;26(11-12):1047-52. doi: 10.1515/jpem-2013-0078. J Pediatr Endocrinol Metab. 2013. PMID: 23843580 Review.
-
Hyponatremia due to preserved non-osmotic arginine vasopressin secretion in adipsic diabetes insipidus: a case report with review of literature.Endocr J. 2024 Nov 1;71(11):1087-1092. doi: 10.1507/endocrj.EJ23-0643. Epub 2024 Aug 7. Endocr J. 2024. PMID: 39111874 Free PMC article. Review.
Cited by
-
Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation.Int J Mol Sci. 2025 May 27;26(11):5131. doi: 10.3390/ijms26115131. Int J Mol Sci. 2025. PMID: 40507941 Free PMC article. Review.
References
-
- NHS England Patient Safety Alert . Risk of severe harm or death when desmopressin is omitted or delayed in patients with cranial diabetes insipidus. London, UK: NHS England, 2016. (https://www.england.nhs.uk/2016/02/psa-desmopressin/)
-
- Atila C, Loughrey PB, Garrahy A, et al. . Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol 2022. 10 700–709. (10.1016/s2213-8587(22)00219-4) - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous